VivoSeq
Other

Botox

0

Pipeline Programs

3

Active Trials

0

Companies Involved

Botox is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

14/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

29

clinical trials

Completed20 · 69%
Recruiting3 · 10%
Terminated3 · 10%
Unknown status2 · 7%
Withdrawn1 · 3%

Trial Activity

29 trials

BoTox Into the Sternocleidomastoid Muscles (SCM)
Recruiting··Phase 4·NCT06903975·30 enrolled
Change in Biting Force After Botox Injection
Completed··N/A·NCT04940104·20 enrolled
Comparative Study of the Effect of Dysport and Botox
Completed··Phase 4·NCT00434863·24 enrolled
Firdapse for Post-BOTOX Vocal Weakness
Completed··Phase 2·NCT05123053·18 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)